NCT05278962View on ClinicalTrials.gov

HF Patients With LVADs Being Treated With SGLT2i

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

SGLT2i

empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage

OTHER

No SGLT2i

No SGLT2i

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER